{Reference Type}: Case Reports
{Title}: Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report.
{Author}: Hamamoto H;Noda M;
{Journal}: Am J Case Rep
{Volume}: 16
{Issue}: 0
{Year}: Dec 2015 7
暂无{DOI}: 10.12659/ajcr.896233
{Abstract}: <B>BACKGROUND: </B>A detailed description is given of a case we encountered in which unexpectedly marked weight gain occurred following a treatment switch from a GLP-1 receptor agonist to an SGLT-2 inhibitor<BR><B>METHODS: </B>The patient, a 44-year-old man with type 2 diabetes mellitus, had gained about 10 kg in weight in the previous year. Therefore, metformin was replaced with liraglutide to obtain reduction of body weight. Although the patient lost about 8 kg (7%), during the 18-month period on the medication, the weight loss stabilized; therefore, the treatment was again switched to tofogliflozin to obtain further reduction of body weight. However, the patient reported increasing hunger and an exaggerated appetite from week 3 onward after the start of tofogliflozin, and gained about 9 kg in weight within 2 weeks, associated with a tendency towards increased HbA1c; therefore, tofogliflozin was discontinued. Immediate reinstitution of liraglutide resulted in reduction of the increased appetite, weight, and HbA1c level.<BR><B>CONCLUSIONS: </B>Caution should be exercised against hyperphagia and weight gain due to hunger that may occur following discontinuation of a GLP-1 receptor agonist and/or initiation of an SGLT-2 inhibitor.